News

Speclipse, Inc., a World leading LIPS and A.I. based medical diagnostic company and the developer of the Spectra-Scope, announced that the commercial use of Spectra-Scope with real skin cancer patients in Australia were shared at the CPCA (Cosmetic Physician College of Australasia) and ACCS (Australasian College of Cosmetic Surgery) CME Meeting, in Sydney, Australia

At the meeting, Samuel Seit, MD, shared his own experience with Spectra-Scope for more than 100 patients after ARTG registration, inclusion ID: 333300 in Australia. He stated that Spectra-Scope is the truly next evolution in skin cancer diagnosis, providing instant, scar-free but highly accurate diagnosis for all types of skin cancer. He emphasized that “Spectra-Scope is an essential diagnostic aid especially when screening multiple irregular moles without sacrificing accuracy". He also stated that "Non-invasive skin cancer diagnosis is beneficial for the patients who are concerned with the traditional biopsy sampling, leaving a biopsy scar behind to deal with on cosmetically sensitive areas such as face, neck or arm etc".

Speclipse, Inc., a World leading LIPS and A.I. based medical diagnostic company and the developer of the Spectra-Scope, providing instant, scar-free but highly accurate diagnosis for all types of skin cancer, announced that MEDTECH OUTLOOK, a medical technology monitoring company, chose Speclipse as top non-invasive device company in 2020.

"Spectra-Scope improves doctors' overall workflow and can be used as a prescreening tool or a secondary confirmation while complimenting a dermatoscope. We noticed that one of our Australian customers achieved diagnostic efficiency by 20~30 percent" said Speclipse CEO, Sung Hyun Pyun, PhD. He also added "Spectra-Scope must be a complement to the biopsy initially by reducing diagnostic procedure time, making data less subjective and improving detection accuracy."

Speclipse, Inc., a World leading LIPS and A.I. based medical diagnostic company and the developer of the Spectra-Scope, providing instant, scar-free but highly accurate diagnosis for all types of skin cancer, announced that it has received CE Medical Device Directive (MDD) certification for Spectra-Scope, the world first LIPS & A.I. based skin cancer diagnostic solution.
​
"CE Mark approval is an important step in the commercialization of Spectra-Scope in European markets, and a signal to shift skin cancer diagnostic market up to more convenient and accurate even at the screening stage" said Speclipse CEO Sung Hyun Pyun, PhD. "With the percentage of skin cancer in the European Region, we believe that millions of people have the potential to benefit from this safe and effective diagnostic option."

Speclipse, Inc., a World-leading LIPS and A.I. based medical diagnostic company and the developer of the Spectra-Scope, providing instant, scar-free but highly accurate diagnosis for all types of skin cancer, announced that Speclipse Australia Pty Ltd, an Australian subsidiary of Speclipse, Inc., has successfully completed the local registration in Australia with its Spectra-Scope, the world first LIPS & A.I. based skin cancer diagnostic solution.
The company said the inclusion is a significant milestone as the Spectra-Scope officially complies with all relevant Australian medical and safety requirements as a Class IIa medical device. “ We will contribute Australian Cancer Community, where it is known that around two in three Australians will be diagnosed with skin cancer by the time they are 70. by providing a safe and reliable diagnostic solution,” said Speclipse CEO Sung Hyun Pyun, Ph.D.

Speclipse, Inc., a World leading LIPS and A.I. based medical diagnostic company and the developer of the Spectra-Scope, providing instant, scar-free but highly accurate diagnosis for all types of skin cancer, announced the company presented Spectra-Scope and its clinical efficacy at 39th ASLMS annual conference, Denver, US.

At the conference, Dr. Girish S. Munavalli, MD, MHS, FACMS presented ”Clinical assessment of a real time, noninvasive, in vivo skin cancer diagnostic device based on laser spectroscopy and deep learning algorithm using aesthetic lasers”. He stated that “Spectra-Scope can pinpoint the probability of a malignant vs. benign lesion within minutes, sparing the patient the pain of a biopsy and dramatically lessening the angst of waiting days to weeks for formal pathology report.”